login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
FOGHORN THERAPEUTICS INC (FHTX) Stock News
USA
- NASDAQ:FHTX -
US3441741077
-
Common Stock
4.53
USD
+0.09 (+2.03%)
Last: 11/12/2025, 4:10:09 PM
4.53
USD
0 (0%)
After Hours:
11/12/2025, 4:10:09 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
FHTX Latest News, Press Relases and Analysis
All
Press Releases
8 days ago - By: Chartmill
- Mentions:
TGE
PAY
FORD
HTZ
...
These stocks are gapping in today's session
5 days ago - By: Benzinga
- Mentions:
PI
AARD
This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
7 days ago - By: Zacks Investment Research
- Mentions:
CVAC
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates
7 days ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
7 days ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
9 days ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
9 days ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
13 days ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
13 days ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
a month ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
a month ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
2 months ago - By: Zacks Investment Research
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know
3 months ago - By: Zacks Investment Research
- Mentions:
ARQT
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
3 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
3 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
3 months ago - By: Zacks Investment Research
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
3 months ago - By: Benzinga
- Mentions:
EQ
AZTR
FGEN
MYO
...
12 Health Care Stocks Moving In Monday's After-Market Session
3 months ago - By: Zacks Investment Research
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
3 months ago - By: Zacks Investment Research
- Mentions:
EXAS
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
3 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
3 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
6 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
6 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
6 months ago - By: Zacks Investment Research
- Mentions:
ATRA
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
6 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
6 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
6 months ago - By: Yahoo Finance
- Mentions:
GGG
SNA
AEO
NVO
Graco Inc. (GGG): Among Benjamin Graham Stocks for Defensive Investors
6 months ago - By: Zacks Investment Research
- Mentions:
INO
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: Zacks Investment Research
- Mentions:
STRO
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
7 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
7 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
7 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
Please enable JavaScript to continue using this application.